Printer Friendly

SUPRA MEDICAL RELEASES SECOND QUARTER RESULTS

 CHADDS FORD, Pa., Nov. 16 /PRNewswire/ -- Supra Medical Corp. (AMEX: SUM.EC) today reported revenues of $38,262 and a net loss of $325,988 or $.01 per share for the second fiscal quarter ended Sept. 30, 1993.
 This compares to revenues of $360,140 and net loss of $472,475 or $.02 per share for the same period in 1992. The company also reported revenues of $202,189 and a net loss of $793,925 or $.03 per share for the 1993 fiscal six months ending Sept. 30. This compares to revenues of $592,056 and a net loss of $1,096,971 or $.05 per share for the same period in 1992.
 Jack Cantwell, chairman and CEO, said, "The results of the second fiscal quarter mask a significant improvement in the company's outlook as preparations were then nearing completion for a major revamping of our entire product line. Subsequent to the quarter's end, Supra announced that its topical hyperbaric oxygen devices are now disposable, less costly and more comfortable for the patient. Further, our ultrasound Supra Scanner(R) system will be available shortly in four Supra Microscanner(R) versions for specific medical applications, i.e., pressure sores, dermatologic conditions, burn assessment, and lymph node involvement. There is a sharp decrease in the end user costs for both product lines, and this advantage should speed our entry into these broad markets."
 Cantwell further observed, "The proof of this promise came as we have just received a $300,000 first order for our disposable topical hyperbaric oxygen products from the Beverly Enterprises nursing home chain, the nation's largest. This order was the outcome of several months of a joint testing and evaluation effort by both companies."
 Supra Medical Corp. develops and markets proprietary medical products which are used in the diagnosis, monitoring and ongoing treatment of skin disorders including skin cancers, burns and various wounds. Additionally, the company is researching the application of its proprietary ultrasound technology to the non-invasive diagnosis of breast disorders.
 For more information, contact George Stasen, COO/EVP, at 800-388-6769.
 /delval/
 -0- 11/16/93
 /CONTACT: George Stasen, COO/EVP of Supra Medical, 800-388-6769/
 (SUM)


CO: Supra Medical Corp. ST: Pennsylvania IN: HEA SU: ERN

MJ-JM -- PH039 -- 5218 11/16/93 16:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1993
Words:378
Previous Article:FORMER DUQUESNE LIGHT CHAIRMAN PHILIP FLEGER DIES
Next Article:HARSCO CORPORATION DECLARES QUARTERLY CASH DIVIDEND
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters